A Phase II HIV Antiviral from France Has Promising Results
Abivax in Paris (France) has released its phase IIa clinical results for an antiviral therapy…
January 13, 2016 - 3 minutes
HIV
€100 Million Investment Round Prepares CureVac For Vaccine Expansion
"The RNA People" at CureVac in Tübingen (Germany) have a new €100M investment into their…
November 3, 2015 - 2 minutes
CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!
One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening…
September 10, 2015 - 3 minutes
InnaVirVax Raises €3.6M to Speed Up its HIV Vaccine
HIV is definitely under the spotlight today. Just after Theravectys' announcement about its phase I/II success, InnaVirVax completed a…
July 20, 2015 - 2 minutes
Theravectys’ HIV Cure on the Road to Success
Theravectys just announced positive results of its HIV drug candidate in a phase I/II study. The therapeutic…
July 20, 2015 - 3 minutes
Abivax launched an Euronext IPO to build up its anti-viral portfolio
Abivax has ended the paperwork and launched its IPO on Euronext Paris, where the biotech…
June 5, 2015 - 1 minute
Theravectys: an Orphan Drug Designation for Its Lentiviral Vector-Based Therapeutic Vaccine
THERAVECTYS, a fully-integrated discovery and clinical development biotechnology company focusing on the development of therapeutic vaccines and immunotherapy,…
February 22, 2015 - 3 minutes
